PALISADE BIO, INC. - 10-Q Filing
Palisade Bio filed its quarterly report for the period ended March 31, 2026, disclosing financial results and updates on agreements including a research program funding agreement with Crohn's & Colitis Foundation. The filing also references equity transactions such as common stock purchase agreements and warrant inducements in October 2025.
Tickers: $PALI